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Serine- and Arginine-rich Proteins 55 and 75 (SRp55 and
SRp75) Induce Production of HIV-1 vpr mRNA by Inhibiting
the 5ⴕ-Splice Site of Exon 3□
S

Received for publication, October 21, 2010, and in revised form, August 4, 2010 Published, JBC Papers in Press, August 4, 2010, DOI 10.1074/jbc.M109.077453

Anna Tranell‡, Eva Maria Fenyö§, and Stefan Schwartz‡¶1
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HIV-1 non-coding exon 3 can either be spliced to exons 4, 4a, 4b,
4c, and 5 to generate tat, rev, and nef mRNAs or remain unspliced
to produce the 13a7 vpr mRNA. Here we show that serine- and
arginine-rich proteins 55 and 75 (SRp55 and SRp75) inhibit splicing from the 5ⴕ-splice site of exon 3 thereby causing an accumulation of the partially unspliced 13a7 vpr mRNA. In contrast, serineand arginine-rich protein 40 (SRp40) induces splicing from exon 3
to exon 4, thereby promoting the production of the 1347 tat
mRNA. We demonstrate that SRp55 stimulates vpr mRNA production by interacting with the previously identified HIV-1 splicing enhancer named GAR and inhibiting its function. This inhibition requires both serine arginine-rich and RNA-binding domains
of SRp55, indicating that production of HIV-1 vpr mRNA depends
on the interaction of SRp55 with an unknown factor.

To produce all the mRNAs that are needed for HIV-1 to be
infectious it uses alternative splicing. The full-length 9-kb transcript contains several splice sites, including four 5⬘-splice sites,
also called splice donors (SD1– 4)2 and eight 3⬘-splice sites, also
called splice acceptors (SA2–3, -4a– c, -5, and -7) (supplemental Fig. 1A), which can all be used in different combinations
to create more than 35 differently spliced mRNAs (supplemental Fig. 1, B and C) (1– 6). Cloning and expression of
individual HIV-1 mRNAs have revealed that mRNAs spliced to
SA3 produce Vpr, those spliced to SA4 produce Tat, those
spliced to SA4a and -4b produce Rev and Nef, and those spliced
to SA5 produce Nef (1, 2, 7, 8). mRNAs spliced to SA2 are
believed to produce Vif (5, 7). Two additional mRNAs that are
believed to produce Rev and Nef are spliced to SA4c or to SA7,
respectively (4). To produce the correct amounts of all mRNAs,
the splice acceptors in HIV-1 are sub-optimal because of short
and interrupted polypyrimidine tracts, non-canonical branch
points, and inhibitory sequences that down-regulate the usage
of several splice sites (6, 9 –13).
Enhancer or silencer sequences regulate alternative splicing
by up-regulating or down-regulating the usage of a splice site
□
S

The on-line version of this article (available at http://www.jbc.org) contains
supplemental Fig. 1.
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(14). Generally, the family of serine- and arginine-rich proteins
(SR proteins) target enhancer sequences, and silencer sequences are targeted by heterogeneous nuclear ribonucleoproteins (15). There are several enhancers and silencers on HIV-1
pre-mRNA (16). A silencer in exon 3 called ESSV inhibits the
vpr splice acceptor SA3 (10, 17). Two silencers in exon 4, named
ESS2 and ESS2p, inhibit splicing into exon 4 thereby inhibiting
the production of tat mRNA (18, 19). SA7 is used by all mRNAs
in the 2-kb class. In exon 7 a silencer called ESS3 blocks U2
small nuclear ribonucleoprotein, thereby suppressing SA7
(19 –21). An intronic silencer that blocks SA7 is located in the
intron, directly upstream of exon 7 (22). An enhancer element
called ESE3 that activates SA7 is located close to ESS3 in exon 7
(9, 21, 23). An enhancer in exon 4 has been named ESE2,
because it attenuates ESS2 and thereby enhances splicing into
SA4 (24). In exon 5, an enhancer named GAR stimulates the
usage of highly active SA5 and adjacent 3⬘-splice sites as well as
SD5, which is used for production of the entire small mRNA
size class (25, 26). HIV-1 vpr mRNA 13a7 contains an intron
between exon 3 and exon 4 and is, therefore, partially spliced.
Little is known about the regulation of vpr mRNA production.
The human SR proteins currently contain at least 10 known
members, including SRp20, SRp30a– c, SRp40, SRp46, SRp54,
SRp55, SRp75, and 9G8. SR proteins regulate alternative splicing by stimulating or repressing the usage of splice sites (27).
The complex splicing of the HIV-1 pre-mRNA indicates that
HIV-1 is dependent on multiple splicing factors to generate all
mRNAs. Recent studies have shown that the relative concentrations of SR proteins are of paramount importance for production of sufficient quantities of the various HIV-1 mRNAs
(16). SR proteins have also been shown to be potential targets
for novel therapy against HIV-1 infection (28). It is therefore of
interest to identify the cellular splicing factors that regulate
HIV-1 mRNA splicing.

EXPERIMENTAL PROCEDURES
Plasmid Constructions—To construct the subgenomic plasmid pDP (Fig. 2A) HIV-1 sequences from position 246 –1571
(all numbers refer to the HXB2R sequence) were PCR-amplified using oligonucleotides BSS and APAA (Table 1) and
cloned into pCR2.1-TOPO (Invitrogen) and subsequently
inserted into pNL13aE (7) using BssHII and SalI, resulting in
pNL13aEBA. Nucleotide 3516 –5348 was PCR-amplified
using oligonucleotides MLUS and SALA (Table 1) and subJOURNAL OF BIOLOGICAL CHEMISTRY
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TABLE 1
Oligonucleotides used for RT-PCR and plasmid construction
Name

Sequence (5ⴕ33ⴕ)

BSS
BAMA
MLUS
SALA
APAA
dGARs

ggcttgctgaagcgcgcacggcaagagg
gccaaggatccgttcactaatcgaatgg
ggggcccggacgcgtatcagaagactgagttacaa
tattctgctatgtcgacaccc
ggtcgacggacgcgtgccctttttcctaggggccctgc
ttaggcatctcctatggcaggaacagtcagactcatcaag
cttctctatc
dGARas
gaagcttgatgagtctgactgttcctgccataggagatgcct
aaggcttt
Downsa4s
agtcgacctagactagagccctggaag
5480s
ggtcgacaagtttgtttcataacaaaagccttag
sd1as
ccgaattcacgcgtaatgatctaagttcttctgatcc
Exon1s
ggtctctctggttagaccagat
Exon1as
cagtcgccgcccctcgcctct
Exon3s
acatagttagccctaggtgtgaatatc
dexon3s
agaggcgaggggcgccgaaaggtaggatctctacaatacttgg
dexon3as
ttgtagagatcctacctttcgccgcccctcgcctcttgcc
sd5as
tgctttgatagagaagcttgat
di3sd3as
gaattcttggtgttattaatgctgctag
SRp55s
aagcgcgcaccatgccacgagtctacatagga
SRp55RRMas
ggctcgagttaatcttcaataagcctaatatt
T7gars
tctaatacgactcactataggggaagaagcggagacagcgacg
T7garas
tgatgagctcttcgtcgctgtctccgcttc
AnnealGARBss/ cgcgcgaagaagcggagacagcgacgaacagctcatcaga
XbaS
acagtcagactcatcaagcttctctatcaaagcat
AnnealGARBss/ ctagatgctttgatagagaagcttgatgagtctgactgt
XbaAS
tctgatgagctcttcgtcgctgtctccgcttcttcg
SRp55gsts
ggggatccatgccgcgcgtctacataggac
SRp55gstas
gggaattcttaatctctggaactcgacctg
757s
gtcgacggtatcgatcggttgtgcgtacaaagcacacacg
L1AM
cgctgggcagccacaggc
gapdhS
aggtcggagtcaacggatttgg
gapdhAS
acagtcttctgggtggcagtgatg

cloned into pCR2.1-TOPO. This fragment was cloned into
pNL13aEBA using MluI and SalI, creating pDP (Fig. 2A).
pNL13a7 has been described previously (7). pNL13a7dG was
constructed by PCR mutagenesis (246 –5522 and 5556 – 8031)
using oligonucleotides BSS, dGARas, dGARs, and BAMA
(Table 1) and cloned into pNL13a7 (7) using SalI and BamHI.
pNL13a7d was generated by PCR amplification of nucleotides
5393– 8031 with oligonucleotides Downsa4s and BAMA (Table
1) and cloning into pCR2.1-TOPO. The fragment was excised
with SalI and BamHI and cloned into pNL13a7. Plasmid
pNL13a7d4 was constructed by PCR amplification of nucleotide 5480 – 8031 using oligonucleotides 5480s and BAMA
(Table 1). The PCR fragment was subcloned into pCR2.1TOPO and subsequently inserted into pNL13a7 using SalI and
BamHI. pNL13a7sd1 was constructed by PCR amplification of
nucleotides 245–569 using oligonucleotides BSS and sd1as
(Table 1). The PCR fragment was subcloned into pCR2.1TOPO and subsequently inserted into pNL13a7 using BssHII
and EcoRI. Transfer of a SalI-BamHI fragment from
pNL13a7dG to pNL13a7sd1 created pNL13a7sd1dG. To generate pNL13a7de3 PCR mutagenesis was performed with oligonucleotides exon1s, dexon3as, dexon3s, and sd5as (1–286 and
5007–5591) (Table 1). The mutated fragment was inserted into
pNL13a7 using BssHII and SalI. Plasmid pNL13a7di3 was constructed by first PCR-amplifying nucleotides 245–289 and
4936 –5055 using oligonucleotides BSS and di3sd3as (Table 1)
followed by cloning into pNL13a7 (7) using BssHII and EcoRI.
The plasmids pT1sd and pT1sde have been described previously (29). Plasmid pT1–5/GAR was generated by first PCRamplifying HIV-1 sequences between nucleotides 5523 and
5591 using oligonucleotides AnnealGARBss/XbaS and AnnealGARBss/XbaAS (Table 1). The PCR fragment was inserted into
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pT1sd using BssHII and XbaI. Plasmid SRp55dRS was generated by PCR amplification of nucleotides 1–543 from SRp55
cDNA using oligonucleotides SRp55s and SRp55RRMAS
(Table 1). The PCR fragment was cleaved with BssHII and XhoI
and cloned into plasmid pCL086 (30). Recombinant plasmid
gst-SRp55 was generated by first PCR-amplifying sequences
from SRp55 cDNA using oligonucleotides SRp55gsts and
SRp55gstas (Table 1). The PCR fragment was cleaved with
BamHI and EcoRI and subcloned into pGEX-2T (Amersham
Biosciences). SR protein expression plasmids have been
described previously (31–33).
Transfections—Transfections of plasmid DNA into HeLa
cells were performed according to the FuGENE 6 method
(Roche Molecular Biochemicals). When nothing else is stated, 1
g of each plasmid was transfected into 60-mm diameter plates
containing subconfluent HeLa cells. Transfected cells were harvested 24 h post-transfection.
RNA Extraction, Northern Blotting, and Radiolabeled DNA
Probe Synthesis—Cytoplasmic RNA extraction was performed
as previously described (34). Northern blot analysis was performed by size separation of 10 g of cytoplasmic RNA on a
1.5% agarose gels containing 2.2 M formaldehyde followed by
transfer of RNA to nitrocellulose filter and hybridization. The
exon1 probe was generated by PCR amplification of nucleotides
1–289 of the HIV-1 genome (HXB2R) with oligonucleotides
Exon1s and Exon1as (Table 1). The probe was [␣-32P]dCTPlabeled by random priming with a Decaprime kit (Ambion Inc.)
according to the manufacturer’s instructions.
RT-PCR—Cytoplasmic RNA was reverse-transcribed at 37 °C
for 50 min using random hexamers as described previously (35).
200 ng of RNA was used for each RT-PCR reaction in a total volume of 20 l. A total of 1 l of cDNA product was PCR-amplified
using the oligonucleotides indicated for each experiment.
siRNA Analysis—Knockdown of protein was performed by
using a pool of four siRNAs targeting SRp55 and four siRNAs
targeting SRp75 (siGENOME SMARTpool, Dharmacon). A
final concentration of 133 nM of each siRNA pool was reversetransfected into HeLa cells at the time of passage. 48 h later,
siRNA-transfected cells growing in 35-mm plates were transfected with 0.5 g of pNL13a7 plasmid DNA as described in the
previous section. Cells were harvested 24 h post plasmid transfection and subjected to RNA extraction and analysis.
Western Blotting—Western blotting was performed as previously described (36).
gst-SRp55 Purification—Purified gst-SRp55 was prepared by
using glutathione-Sepharose (GS) beads as specified by the
manufacturer (Amersham Biosciences). Briefly, a culture of
Escherichia coli BL21 transformed with pGEX-SRp55 was
induced with 0.1 mM isopropyl-␤-D-thiogalactopyranoside for
2 h. The bacteria were pelleted and resuspended in ice-cold
phosphate-buffered saline and lysed by sonication followed by
incubation in 1% Triton X-100. Debris was pelleted, and gstSRp55 was purified using the GS-beads.
In Vitro Transcription and RNA Gel Shift Assay—In vitro
transcription was performed on a PCR fragment containing
bacteriophage T7 promoter upstream of GAR using T7 RNA
polymerase (Ambion Inc.). The control RNA was transcribed
from a T7 promoter-driven plasmid encoding a sequence from
VOLUME 285 • NUMBER 41 • OCTOBER 8, 2010
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induced by Rev (supplemental
Fig. 1C). To identify proteins that
rev
regulate vpr expression, we used a
nef
cDNA plasmid named pNL13a7
SD3
SA4
that expresses the 13a7 vpr mRNA
SA4b SA5
SA4a
BAMA
Exon3s
Exon 1 probe
(7) (Fig. 1A). However, the majority
SA4c
of this mRNA is further spliced
13a7
1347
from the unique 5⬘-splice site of
134c7
exon 3 to exons 4, 4a, 4b, 4c, or 5 (7)
134a7
(Fig. 1A). Northern blotting on
134b7
cytoplasmic RNA extracted from
1357
cells transfected with pNL13a7 and
SR protein expression plasmids
c
0
0c
0
5
5
20 30 40 55 75 5
p2 p3 Rp4 Rp5 Rp7 C35
revealed that SRp40 shifted the
M - - SRp SRp SRp SRp SRp SC3
SR SR
S
S
S
S
splicing of mRNAs generated by
1000
13a7 vpr
13a7 vpr
pNL13a7 to mRNAs migrating
500
1347 tat
134c7 rev
1347 tat
higher up in the gel (Fig. 1B). SRp55
298
1357 nef
1357 nef
and SRp75 totally inhibited splicing
200
and promoted production of high
levels of unspliced 13a7 vpr mRNA
Exon3s-BAMA
in the cytoplasm (Fig. 1B). In congapdh
trast, SRp20, SRp30c, and SC35 had
gapdh
an unspecific inhibitory effect on
0 55
5
4
7
expression of the HIV-1 mRNAs
p Rp
p
SR SR
S
(Fig. 1, B and C). RT-PCR with oligonucleotides Exon3s and BAMA
(Fig. 1A) showed that SRp40
SR-proteins
induced production of tat mRNAs
spliced from exon 3 to exon 4 (Fig.
1C) and that SRp55 and SRp75
inhibited splicing. The latter proteins increased the levels of
Enolase
unspliced 13a7 vpr mRNA at the
FIGURE 1. A, schematic representation of the HIV-1 subgenomic plasmid pNL13a7 (7). The mRNAs produced expense of all spliced HIV-1
from the plasmid are indicated below as well as the oligonucleotides used for RT-PCR and probe used for mRNAs (Fig. 1C). Taken together,
northern blotting. B, Northern blot of total cytoplasmic RNA extracted from HeLa cells transfected with
pNL13a7 (7) in the absence or presence of CMV promoter-driven plasmids expressing SRp20, SRp30c, SRp40, the results in Fig. 1, B and C, demSRp55, SRp75, or SC35. The blot was probed with exon 1 probe (A) detecting all HIV-1 mRNAs. Various mRNAs onstrate that SRp40 enhances splicdetected by the probe are indicated. C, RT-PCR on the RNA used in B performed with oligonucleotides Exon3s ing from exon 3 to exon 4, whereas
and BAMA (A). Bands representing mRNAs are indicated. M represents the molecular weight marker. D, SR
proteins were detected by Western blot analysis using monoclonal antibody 1H4. Monoclonal antibody detec- SRp55 and SRp75 inhibit splicing
tion of enolase was used as loading control.
from exon 3 and promote production of 13a7 vpr mRNA. Western
human papilloma virus type 1 named AUM/UM (34). The blot analysis showed expression of SR protein from the SR proRNAs were labeled with [␣-32P]CTP, and competitor GAR tein expression plasmids (Fig. 1D).
Overexpression of SRp55 and SRp75 Induces Production of
RNA was synthesized in the absence of radiolabeled nucleotide. RNA gel-shift assays were performed with gst-SRp55 or 13a7 vpr mRNA in the Context of the Sub-genomic HIV-1 Plasgst at room temperature in 20 l of binding buffer (120 mM KCl, mid pDP—We wished to study the effect of SR proteins on vpr
10 mM HEPES (pH 7.6), 3 mM MgCl2, 1 mM dithiothreitol, and mRNA in the context of all HIV-1 splice sites present. We con5% (v/v) glycerol). After 20 min the RNA-protein complexes structed a plasmid named pDP (Fig. 2A) that contains the entire
were resolved on non-denaturing 7.5% polyacrylamide gels HIV-1 genome except for a 2-kb deletion in the pol gene. Oli(acrylamide-bisacrylamide, 29:1). The complexes were visual- gonucleotide Exon3s was used in combination with oligonucleotide BAMA to specifically detect mRNAs that contain exon
ized by autoradiography.
3 and 3a (supplemental Fig. 1, C and A). The results revealed
RESULTS
that SRp40 redirected splicing from production of primarily
SRp55 and SRp75 Inhibit Splicing from Exon 3 and Induce 1357 mRNA to 1347 tat mRNA, as expected (Fig. 2B). In conProduction of 13a7 vpr mRNA—The HIV-1 vpr mRNA is trast, SRp55 inhibited splicing from exon 3 and induced proencoded by mRNAs containing either exon 3a or 3aE duction of 13a7 vpr mRNA from pDP (Fig. 2B). Northern blot(supplemental Fig. 1, A and B). vpr mRNA 13a7 is special in that ting of HIV-1 mRNAs produced from pDP in the absence or
it is incompletely spliced, but lacks the RRE and thus cannot be presence of serially diluted SRp55 revealed that high levels of
vpr
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pDP:

1571

tat

3516

rev
env

vif

gag

vpr

pol

SD1

SD3
SD2
SA2
SA3

LTR

SD5

nef

vpu
SA7

LTR

SA5
SA4b
SA4a
SA4c
SA4

mRNAs:

unspliced pDP mRNA
4 kb
13a7 vpr mRNA
2 kb
Exon 1s

Exon 3s

BAMA

BSS
Exon1 probe
M

-

-

SRp55

SRp40 SRp55

SRp75
-

-

unspliced
pDP mRNA

1500
850

4 kb

13a7 vpr

400

1347 tat

200

1357 nef

*
2 kb

Exon3s - BAMA
gapdh

0

4
Rp

-

M - - S

1000
13a7 vpr
500

p5
5

M -

SRp75

SR

SRp55

500
298
200

75

p
SR

147 tat

157 nef

1347 tat
1357 nef

200

BSS - BAMA
gapdh
Exon3s - BAMA
gapdh
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same RNA samples with the exon
3-specific oligonucleotides Exon3s
rev
vif
and BAMA (Fig. 2D). These experigag
env
vpr
pol
nef
ments demonstrated a robust increase in production of 13a7 vpr
vpu
SD1
SD3
mRNA in an SRp55- or SRp75-dose5’
splice
sites:
257
568
dependent manner (Fig. 2D).
sd1: cugGUgagu
Induction of 13a7 vpr mRNA by
sd3: aagGUagga
311 nt
SRp55
and SRp75 Is Dependent on
optimal: cagGUaagu
SD3 in Exon 3—To investigate
vpr
tat
pNL13a7sd1:
if SRp55 and SRp75 inhibited SD3
rev
specifically, we replaced splice
nef
donor 3 (SD3) in pNL13a7 with
SD1
splice donor 1 (SD1) from pDP,
257
5289
resulting in pNL13a7sd1 (Fig. 3A).
SRp55
SRp75
SRp55 and SRp75 did not induce
production of unspliced vpr mRNA
sd1 sd1 w
w w sd1 sd1 w w
w sd1 sd1
from plasmid pNL13a7sd1 with
vpr/vpr*
SD1, whereas high levels of
tat
unspliced 13a7 vpr mRNA were
nef
induced from wild-type plasmid
pNL13a7 with SD3, as expected
gapdh
(Fig. 3B). RT-PCR confirmed that
SRp55 and SRp75 primarily induced
production of unspliced 13a7 vpr
SRp40
SRp75
SRp55
mRNA in the presence of SD3 (Fig.
M w sd1 w
sd1 w
sd1
M w w sd1 sd1 w sd1
1500
3C), whereas SRp55 and SRp75
850
tat
1000
induced production of 1347 tat
vpr
500
nef
400
tat
mRNA in the presence of SD1 (Fig.
298
200
3C). Overexpression of SRp75 also
200
nef
strongly induced splicing to a crypExon1s-BAMA
tic splice acceptor in exon 5, in the
gapdh
presence of SD1 (Fig. 3C). SRp40
Exon1s-BAMA
induced production of tat mRNA
gapdh
independently of SD1 or SD3 and
did not inhibit splicing to produce
FIGURE 3. A, schematic representation of the HIV-1 subgenomic plasmids pDP and pNL13a7sd1. Nucleotide
positions of the deletions and insertions are indicated. The sequences of the different splice donors SD1 and vpr mRNA 13a7 as shown by RTSD3 are shown and compared with an optimal U1 snRNA binding site. B, Northern blot of cytoplasmic RNA PCR (Fig. 3D). In conclusion, SRp55
extracted from HeLa cells transfected with pNL13a7 (w) (7) or pNL13a7sd1 (sd1) in the absence or presence of
CMV promoter-driven plasmids expressing SRp55 or SRp75. The blot was probed with exon 1 probe (Fig. 2A), and SRp75 stimulate splicing from
detecting all HIV-1 mRNAs. Identified mRNAs are indicated. C, the RNAs in B were subjected to RT-PCR with SD1 to SA4 to generate 147 tat
oligonucleotides Exon1s and BAMA (Fig. 1A) detecting all mRNAs. Bands representing mRNAs are indicated. M mRNA and inhibit splicing from
represents the molecular weight marker. Gapdh amplification was used as a control. D, RT-PCR performed on
cytoplasmic RNA extracted from HeLa cells transfected with HIV-1 subgenomic plasmids pNL13a7 (w) or SD3 to generate 13a7 vpr mRNAs.
pNL13a7sd1 (sd1) in the absence or presence of CMV promoter-driven plasmid-expressing SRp40. Oligonu- To confirm that SRp55 and SRp75
cleotides Exon1s and BAMA (Fig. 1A) were used to detect all HIV-1 mRNAs. The bands representing mRNAs are had different effects on SD1 and
indicated. M represents the molecular weight marker.
SD3 also in the context of the subSRp55 caused production of mRNAs migrating higher than the genomic HIV-1 expression plasmid pDP, in which all HIV-1
2-kb mRNAs detected in the absence of exogenous SRp55 (Fig. splice sites are present, we analyzed mRNAs produced from
2C). SRp75 had a similar effect on the mRNAs produced from pDP in the absence or presence of SRp40, SRp55, and SRp75
pDP (Fig. 2C). This was confirmed by RT-PCR analysis of the with primers that were specific for mRNAs spliced at SD1 (BSS
pDP:

tat

FIGURE 2. A, schematic representation of the HIV-1 subgenomic plasmid pDP, which is derived from pNL43 (48) and contains a deletion between nucleotides
1571 and 3516 (numbers refer to HXB2R sequence). The three HIV-1 mRNA size classes, and vpr mRNA 13a7, are indicated below plasmid pDP. Arrows indicate
oligonucleotides used for RT-PCR. The Northern blot probe is indicated. B, RT-PCR on cytoplasmic RNA extracted from HeLa cells transfected with pDP in the
absence or presence of pCMVSRp40 or pCMVSRp55. Duplicate transfections are shown. The RT-PCR was performed with the oligonucleotides Exon3s
and BAMA (A). The different bands represent the indicated mRNAs. C, Northern blot of cytoplasmic RNA extracted from HeLa cells transfected with pDP
in the absence or presence of increasing concentrations of pCMVSRp55 or pCMVSRp75. The mRNA size classes are indicated. *, the shift in migration of
2-kb mRNAs. D, the RNAs in C were used for RT-PCR with oligonucleotides Exon3s and BAMA (A) that detect mRNAs containing exon 3. E, RT-PCR on
cytoplasmic RNA extracted from HeLa cells transfected with pDP in the absence or presence of pCMVSRp40, pCMVSRp55, or pCMVSRp75. The RT-PCR
was performed with the oligonucleotides BSS and BAMA (A) detecting all HIV-1 mRNAs. The bands representing mRNAs are indicated. M represents the
molecular weight marker.
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SRp55 and SRp75 induced production of unspliced 13a7 vpr mRNA in
nef
the absence of exon 3 sequences
(Fig. 4B) or intron 3 sequences (Fig.
SD3
SA4
SA4b SA5
SA4a
4C). However, the inhibitory effect
SA4c
of SRp75 on vpr mRNA splicing was
vpr
pNL13a7de3:
lower in the absence of exon 3 (data
tat
rev
35 007
9
not shown). In addition, we ob5
4
nef
( )
served that the deletion in exon 3
SD3
SA4
SA4b SA5
increased splicing efficiency (Fig.
SA4a
SA4c
4B), probably due to deletion of prevpr
pNL13a7di3:
viously described splicing inhibitory
tat
89
rev
55
sequences (10, 17). In contrast, the
2
0
5
5
nef
deletion in intron 3 reduced splicing
( )
SD3
SA4
SA4b SA5
efficiency (Fig. 4C), suggesting that
SA4a
SA4c
splicing regulatory elements may be
located downstream of exon 3. We
SRp55
SRp75
SRp55
concluded that SRp55 and SRp75
w w di3 di3 w w di3 w
w di3 di3
w w de3 de3 w w de3 de3
targeted other HIV-1 sequences
than those of exon 3 or the intronic
13a7 vpr
13a7 vpr
region between exon 3 and exon 4.
1347 tat
1347 tat
Deletions in Exon 4, Upstream of
1357 nef
1357 nef
Exon 5, Do Not Affect the Ability of
SRp55 and SRp75 to Induce Production of Unspliced 13a7 vpr mRNA,
gapdh
gapdh
But Affect the Ability of SRp40 to
FIGURE 4. A, schematic representation of HIV-1 subgenomic plasmids pNL13a7 (7), pNL13a7de3, and Induce Tat mRNA Splicing—A repNL13a7di3. Nucleotide positions of deletions are indicated. B and C, Northern blots with RNA extracted from
HeLa cells transfected with pNL13a7 (w), pNL13a7de3 (de3), or pNL13a7di3 (di3) in the absence or presence of gion in exon 4 described as a
CMV promoter-driven plasmids expressing SRp55 or SRp75. The blots were probed with exon 1 probe (Fig. 1A) splicing enhancer (ESE2) (24) was
detecting all HIV-1 mRNAs. Detected mRNAs are indicated.
deleted in pNL13a7, resulting in
pNL13a7d (Fig. 5A). The deletion of
and BAMA) and with primers that are specific for mRNAs ESE2 was analyzed by Northern blotting and RT-PCR, and the
using SD3 (Exon3s and BAMA). The locations of the primers results revealed that deletion of ESE2 reduced splicing effiare shown in Fig. 2A. The results shown in Fig. 3 predicted that ciency (Fig. 5, B and C) as expected. Northern blot experiments
SRp40 should enhance splicing to exon 4 from both SD1 and also showed that deletion of ESE2 in exon 4 did not affect the
SD3 to produce 147 and 1347 tat mRNAs, respectively. RT-PCR ability of SRp55 and SRp75 to induce production of 13a7 vpr
with primer pairs Exon3s and BAMA revealed that SRp40 mRNA (Fig. 5B). This finding was confirmed by RT-PCR (Fig.
induced splicing from SD3 to exon 4 to produce 1347 tat mRNA 5C). In addition, the ability of SRp40 to redirect splicing to exon
(Fig. 2B), and RT-PCR with primers BSS and BAMA revealed 4 was largely independent of ESE2 (Fig. 5, B and C). However,
that SRp40 induced splicing from SD1 to exon 4 to produce 147 introduction of a larger deletion in exon 4 (pNL13a7d4) (Fig.
5A) reduced the ability of SRp40 to induce 1347 tat mRNA (Fig.
tat mRNA (Fig. 2E).
The results shown in Fig. 3 also predicted that SRp55 and 5D). The same deletion did not affect the ability of SRp55 and
SRp75 should enhance splicing to exon 4 from SD1 to produce SRp75 to induce the production of unspliced 13a7 vpr mRNA
147 tat mRNAs, but should inhibit splicing from SD3, to gen- (Fig. 5D). We concluded that SRp40 was dependent on seerate the 13a7 vpr mRNA. This was indeed the case, as RT-PCR quences in exon 4, whereas the target sequence of SRp55 and
with primer pairs Exon3s and BAMA revealed that SRp55 and SRp75 most likely is located downstream of nucleotide position
SRp75 inhibited splicing from SD3 to exon 4 to produce 13a7 5478 in exon 4.
Splicing to Exons 4a, 4b, 4c, and 5 in vpr cDNA 13a7 Is
vpr mRNA (Fig. 2, B and D), whereas RT-PCR with primers BSS
and BAMA revealed that SRp55 and SRp75 induced splicing Reduced When a Previously Identified Splicing Regulatory Elefrom SD1 to exon 4 to produce 147 tat mRNA (Fig. 2E). We ment in Exon 5, Termed GAR, Is Deleted—We had established
concluded that high levels of SRp55 and SRp75 enhanced splic- that neither exon 3 nor intron 3, nor exon 4 sequences
ing from SD1 to exon 4 and inhibited splicing from SD3 to upstream of exon 5, were required for the splicing inhibitory
effect of SRp55 and SRp75. Next we investigated if SRp55 or
induce production of 13a7 vpr mRNA.
Inhibition of the 5⬘-Splice Site of Exon 3 by SRp55 and SRp75 SRp75 acted on the remaining sequences of exon 4 that overlap
Is Not Dependent on Sequences in Exon 3 or Intron 3—To iden- with exon 5 and contain a previously identified exonic splicing
tify HIV-1 sequences that were targeted by SRp55 and SRp75, enhancer named GAR (25, 26) (Fig. 6A). Deletion of GAR in
deletions were introduced in exon 3 or intron 3 (sequences pNL13a7, generating pNL13a7dG (Fig. 6A), resulted in mainly
between SD3 and SA4) in pNL13a7 (Fig. 4A). Overexpression of unspliced 13a7 vpr mRNA production, as can be seen by Northvpr

pNL13a7:

tat

rev
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tion and overexpression of SRp55
and SRp75 indicated that SRp55 and
SD3
SA4
SA5
SRp75 might act at least partly by
SA4b
SA4a
inhibiting GAR.
SA4c
3
7
9
GAR
3
53
53
To investigate the relationship
(
)
pNL13a7d
between GAR and SRp55 further,
SD3
SA4
SA5
SA4b
we replaced SD3 with SD1 in the
SA4a
SA4c
78
37
4
3
5
GAR
GAR-deleted pNL13a7 plasmid,
5
(
)
pNL13a7d4
resulting in pNL13a7sd1dG (Fig.
SD3
SA4
SA5
6A). Previous results shown in Fig.
SA4b
SA4a
SA4c
3, B and C, predicted that SRp55
should induce splicing from SD1
0
5
5
5
0
5
p4 Rp5 Rp7
p7
p4
p5
(the 5⬘-splice site of exon 1) to SA4
R
R
R
R
S
S
S
S
S
S
(the 3⬘-splice site of exon 4) and that
M
w
w
d
d
w
d
w
d
w
d
w w d d w d w d w d
it
should not inhibit splicing from
1000
13a7 vpr
SD1.
As predicted, SRp55 induced
13a7 vpr
500
1347 tat
splicing
to exon 4 in the presence
1357 nef
1347 tat
of SD1 in pNL13a7sd1 but failed to
298
affect splicing when GAR was
200
1357 nef
deleted in the same plasmid
gapdh
(pNL13a7sd1dG) (Fig. 6E) support137 nef*
ing the idea that SRp55 acts through
75
40
55
Exon3s-BAMA
GAR.
Rp
Rp
Rp
S
S
S
The phenotype of pNL13a7sd1dG
gapdh
M w w d4 d4 w d4 w d4 w d4
was similar to the phenotype of
pNL13a7dG (Fig. 6, C and E). SRp55
1000
did not alter the splicing of
13a7 vpr
500
pNL13a7sd1dG, whereas induction
1347 tat
298
of splicing from SD1 to SA4 was
1357 nef
seen when GAR was present
200
137 nef*
(pNL13a7sd1) (Fig. 6E). We conExon3s-BAMA
cluded that GAR is required for
splicing to exons 4a, 4b, 4c, and 5,
gapdh
and that at least part of the splicing
FIGURE 5. A, schematic representation of a segment of HIV-1 subgenomic plasmids pNL13a7 (7), pNL13a7d, inhibitory effect of SRp55 and
and pNL13a7d4. Nucleotide positions of deletions are indicated. B, Northern blot with RNA extracted from
HeLa cells transfected with pNL13a7 (w) or pNL13a7d (d) in the absence or presence of CMV promoter-driven SRp75 was through GAR.
plasmids expressing SRp40, SRp55, or SRp75. The Northern blot was probed with exon 1 probe (Fig. 1A)
SRp55 Inhibits the Function of
detecting all HIV-1 mRNAs. Detected mRNAs are indicated. C, RT-PCR with oligonucleotides Exon3s and BAMA GAR in the Absence of Other HIV-1
(Fig. 1A) performed on the RNAs also analyzed in B. Bands representing mRNAs are indicated. M represents the
molecular weight marker. D, RT-PCR on RNA extracted from HeLa cells transfected with pNL13a7 (w) or Sequences—To further substantiate
pNL13a7d4 (d4) in the absence or presence of plasmids expressing SRp40, SRp55, and SRp75. The oligonucleo- the finding that SRp55 inhibits the
tides used were Exon3s and BAMA (Fig. 1A). Bands representing mRNAs are indicated. M represents the molecfunction of GAR specifically, we
ular weight marker.
inserted a 69-nucleotide HIV-1
ern blotting (Fig. 6B) and by RT-PCR (Fig. 6C). This deletion sequence encoding exon 5 and containing the GAR sequence
inhibited splicing from exon 3 to exons 4a, 4b, 4c, and 5, but (Fig. 7B) into an enhancerless human papillomavirus type 16
enhanced splicing to exon 4 (Fig. 6, B and C). Overexpression of (HPV-16) plasmid named pT1sd (29) (Fig. 7A). This plasmid
SRp40 with the GAR deletion mutant pNL13a7dG resulted in a has the potential to produce HPV-16 L1 mRNAs, which contain
very inefficient induction of 1347 tat mRNA, indicating that an internal exon, and L1i mRNAs, which lack the internal exon
SRp40 was dependent on GAR (Fig. 6C), as expected from pre- (Fig. 7A). Transfection of pT1sd plasmid into HeLa cells gives
viously published results (25). Similar results were obtained by rise to primarily L1i mRNA as the splicing enhancer in the
Northern blotting (Fig. 6D). However, because low levels of tat internal exon has been deleted (Fig. 7C). If the HIV-1 GAR
mRNA were detected in the presence of SRp40 (Fig. 6C), SRp40 enhancer or the core HPV-16 enhancer (E) was added back into
may act also through other sequences than GAR. Overexpres- the internal exon of pT1sd to generate pT1–5/GAR and pT1sde
sion of SRp55 and SRp75 did not alter the phenotype of the (29), respectively (Fig. 7A), splicing shifted to L1 mRNA (Fig. 7C).
pNL13a7dG (Fig. 6B). However, RT-PCR analysis revealed that These results confirmed previously published results that GAR
the induction of 1347 tat mRNA, caused by the deletion of acts as a splicing enhancer in a heterologous context (25, 26).
If SRp55 inhibits the function of GAR specifically, overexGAR, was inhibited by SRp55 and SRp75 (Fig. 6C). Although
SRp55 and SRp75 could still inhibit the 5⬘-splice site of exon 3 pression of SRp55 should restore production of L1i mRNA
in the absence of GAR, the similar phenotype of the GAR dele- from pT1–5/GAR, but not from pT1sd or pT1sde. The three
ESE2

GAR

pNL13a7

OCTOBER 8, 2010 • VOLUME 285 • NUMBER 41

JOURNAL OF BIOLOGICAL CHEMISTRY

31543

SRp55 Induces vpr mRNA Production
SRp55 Interacts Directly with the
GAR Splicing Enhancer in Exon 5—
SD3
SA4
SA5
We speculated that SRp55 binds
SA4b
SA4a
directly to GAR. Indeed, the
SA4c
ESE2
(
)
pNL13a7dG
ESEfinder威 (37, 38) predicted an
SD3
SA4
SA5
SRp55 binding site in GAR (Fig. 8A)
SA4b
SA4a
as previously reported (25). To
SA4c
ESE2
determine if SRp55 was binding to
(
)
pNL13a7sd1dG
GAR, an RNA gel shift assay was
SD1
SA4
SA5
SA4b
performed with gst-SRp55 and
SA4a
SA4c
radiolabeled exon 5 GAR RNA (Fig.
5
5
0
8A). These experiments demonSRp75
SRp55
p4 Rp5 Rp7
S
S
SR
strated that gst-SRp55 could bind
w dg
w
dg
w
dg
M w w dg dg w dg w dg w dg
directly to GAR (Fig. 8B). In competition
experiments, unlabeled GAR
1000
13a7 vpr
13a7 vpr
500
RNA
inhibited SRp55 binding to
1347 tat
1347 tat
1357 nef
radiolabeled
GAR RNA, indicating
298
that
the
binding
of SRp55 to the
200
1357 nef
GAR
enhancer
was
specific (Fig.
137 nef
8B). Gst-SRp55 did not bind to a
gapdh
control RNA derived from human
Exon3s-BAMA
papillomavirus type 1 named AUM/
gapdh
UM (34) (Fig. 8C), further supporting that SRp55 binds specifically to
SRp40
SRp55
HIV-1 GAR.
w
w dg dg w w dg dg
M sd1 sd1dg sd1 sd1dg
SRp55 and SRp75 Counteract the
Effect
of SRp40 on HIV-1 Splicing—
500
vpr*
13a7 vpr
Having established that SRp40 and
147 tat
1347 tat
SRp55 had different effects on
298
1357 nef
HIV-1 vpr mRNA 13a7 and consid200
157 nef
ering that SRp40 as well as SRp55
Exon1s-BAMA
gapdh
can act through GAR, we investigapdh
gated if SRp40 and SRp55 were
competing for GAR. Transfection of
FIGURE 6. A, schematic representation of segments of the HIV-1 subgenomic plasmids pNL13a7 (7),
pNL13a7dG, and pNL13a7sd1dG. B and D, Northern blot with RNA extracted from HeLa cells transfected with pNL13a7 with a constant, high
pNL13a7 (w) or pNL13a7dG (dg) in the absence or presence of CMV promoter-driven plasmids expressing amount of SRp40 and a serial diluSRp40, SRp55, or SRp75. The blots were probed with exon 1 probe (Fig. 1A). All detected mRNAs are indicated.
C, RT-PCR with RNA extracted from HeLa cells transfected with pNL13a7 (w) or pNL13a7dG (dg) in the absence tion of either SRp55 or SRp75
or presence of CMV promoter-driven plasmids expressing SRp40, SRp55, or SRp75. RT-PCR oligonucleotides showed that SRp40 induced proExon3s and BAMA (Fig. 1A) were used. The bands representing mRNAs are indicated. M represents the molec- duction of tat mRNA 1347 in the
ular weight marker. E, RT-PCR with RNA extracted from HeLa cells transfected with pNL13a7sd1 (sd1) (Fig. 3A)
or pNL13a7sd1dG (sd1dg) in the absence or presence of CMV promoter-driven plasmid expressing SRp55. presence of low levels of SRp55 and
Oligonucleotides used for RT-PCR were Exon1s and BAMA (Fig. 1A). Bands representing mRNAs are indicated. SRp75, as expected (Fig. 9A). HowM represents the molecular weight marker.
ever, increasing the levels of SRp55
or SRp75 resulted in a shift toward
subgenomic HPV-16 plasmids were transfected in the absence production of mainly unspliced vpr mRNA 13a7 (Fig. 9A). We
or presence of SRp55 plasmid. The results revealed that SRp55 concluded that production of tat mRNA 1347 or vpr mRNA
altered the splicing pattern of pT1–5/GAR by inducing L1i 13a7 is determined by the relative concentration of SRp40 vermRNAs (Fig. 7C). This is a result of exclusion of HPV-16 inter- sus SRp55 or SRp75. If this competition was solely due to a
nal exon that is depending on a functional enhancer down- competition for binding to GAR, an SRp55 mutant with
stream of HPV-16 3⬘-splice site at nucleotide position 3358 retained RNA-binding domains, but without the RS domain,
(Fig. 7C). This effect was specific for the GAR-containing should function equally well or better than wild-type SRp55.
HPV-16 plasmid pT1–5/GAR, because the plasmids without Overexpression of SRp55-dRS, which lacks the RS domain,
GAR (pT1sd and pT1sde) were unaffected by SRp55 (Fig. 7C). failed to inhibit splicing and production of 13a7 vpr mRNA (Fig.
The effect of SRp55 was concentration-dependent, but splicing 9B). We concluded that the mechanism of inhibition of SD3 is
did not shift completely from L1 to L1i (Fig. 7D), not even in the more complex than simply competing with SRp40 for binding
presence of 10 g of co-transfected SRp55 plasmid. These to GAR, because inhibition was dependent on the RS domain of
results suggested that GAR acted very efficiently even in con- SRp55. Taken together, our results suggested that SRp55 intertext of HPV-16. We concluded that SRp55 specifically inhibits acts with GAR and inhibits splicing from exon 3 by interacting
with an unidentified factor.
the function of the HIV-1 GAR splicing enhancer.
ESE2

GAR

pNL13a7
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These results suggest that knockdown of SRp55 and SRp75 enhanced splicing of the 13a7 vpr
mRNA and support a role for SRp55
and SRp75 in the production of partially spliced HIV-1 vpr mRNAs.

DISCUSSION
pT1sde
E2
We show that overexpression of
L2
E4
E5
E1
L1
CMV
()
SRp55 specifically inhibits splicing
from the 5⬘-splice site of HIV-1
757s
L1AM
exon 3. High levels of SRp55 overL1
ride all splicing enhancers in exons 4
E
L1i
and 5, including ESE2 (24) and GAR
(25, 26), causing splicing inhibition
5/GAR
pAE
pAL
pT1-5/GAR
from exon 3 and production of the
E2
L2
E4
E5
E1
L1
CMV
partially spliced 13a7 vpr mRNA.
()
We demonstrate that SRp55 inhibits GAR, suggesting a model in
757s
L1AM
which SRp55 interferes with the
L1
5/GAR
GAR-enhancer to inhibit splicing to
L1i
exons 4a, 4b, 4c, and 5, at least from
the 5⬘-splice site of exon 3. We also
5/GAR: gaagaagcggagacagcgacgaagagctcatcagaacagtcagactcatcaagcttctctatcaaagca
found that SRp55 simultaneously
SRp55
- +
- +
+
+ +
enhances splicing from exon 1 to
pT1-5/GAR
pT1sde
pT1-5/GAR
M pT1sd
exon 4 to produce tat mRNA, sugSRp55 (ug):
0
10
3
1000
gesting that production of tat
850
mRNA is less GAR-dependent than
400
400
rev and nef mRNAs and that SRp55
L1
L1
acts also on RNA elements in exon
200
200
L1i
4. We speculate that these interacL1i
tions inhibit splicing when the
757s-L1AM
5⬘-splice sites is weak, as in exon 3
gapdh
(Fig. 3A), whereas, in combination
with the stronger 5⬘-splice site of
exon 1, these interactions redirect
50
splicing to exon 4. Although we
757s-L1AM
identified GAR as one target for the
gapdh
splicing inhibitory effect of SRp55, it
remains to be determined how
FIGURE 7. A, schematic representation of the HPV-16 subgenomic plasmids pT1sd and pT1sde (29) as well as
the HPV-16 subgenomic plasmid containing the HIV-1 exon 5 sequence, including the GAR sequence (25, 26), SRp55 directs splicing from exon 1
pT1–5/GAR. The L1 and L1i mRNAs produced from these plasmids are indicated. Arrows indicate PCR oligonu- to exon 4.
cleotides 757s and L1AM used for RT-PCR. B, the HIV-1 sequence inserted in pT1sd is shown with the GAR
There are multiple splicing ensequence indicated in bold. C, RT-PCR, with oligonucleotides 757s and L1AM, on RNA extracted from HeLa cells
hancer
elements in exons 4 and 5
transfected with pT1sd, pT1sde, or pT1–5/GAR in the absence or presence of CMV promoter-driven plasmid
expressing SRp55. Bands representing L1 or L1i mRNAs are indicated. M represents the molecular weight (16). Whereas SC35 binds to enmarker. D, RT-PCR on RNA extracted from HeLa cells transfected with pT1–5/GAR in the absence or presence of
hancer ESE2 (24), potential binding
various concentrations of SRp55 plasmid. M represents the molecular weight marker.
sites for ASF/SF2, SRp40, and
SRp55 were identified in GAR (25).
To investigate if SRp55 and SRp75 were required for gener- Previously published in vitro splicing experiments revealed that
ation of the low levels of 13a7 vpr mRNA produced from SRp40 and ASF/SF2 act through GAR (25, 26), whereas no
pNL13a7 in the absence of exogenous SRp55 or SRp75, we per- enhancing effect was seen with SRp55 (25). Our experiments
formed an siRNA-mediated knockdown of endogenous SRp55 are in agreement with these published results and confirm that
and SRp75 in cells transfected with pNL13a7. The results deletion of GAR in subgenomic HIV-1 plasmids abrogates prorevealed that the levels of unspliced 13a7 vpr mRNA produced duction of rev and nef mRNAs, whereas tat mRNAs are unaffrom the vpr cDNA pNL13a7 were reduced when SRp55 and fected (25). In addition, we confirm that GAR can act as a potent
SRp75 levels were knocked down (Fig. 9C). A scrambled siRNA splicing enhancer on heterologous mRNAs. We showed that
and siRNAs against unrelated targets did not affect the levels of insertion of GAR downstream of the major HPV-16 3⬘-splice
13a7 vpr mRNA produced from pNL13a7 (data not shown). site SA3358 efficiently enhanced splicing in the context of
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including the site in GAR, to enhance
production of exon 4 containing tat
mRNAs.
SRp40 appears to induce procompetitor
5
p5
duction
of exon 4-containing tat
SR
+
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+
+
gst SRp55
t
t
gs gs
mRNA from various 5⬘-splice sites.
+
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gar
+
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+
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+
Our experiments demonstrate that
SRp55 overrides the induction of tat
mRNA 1347 by SRp40. In the presbound probe
ence of high levels of SRp40 a strong
free probe
induction of splicing to exon 4 (SA4)
occurs. However, overexpression of
FIGURE 8. A, representation of GAR sequence used as probe for RNA gel shift assay. Potential binding sites for SRp55 inhibits splicing from SD3
SRp40 and SRp55 are indicated according to ESEfinder姞 (37, 38). B, RNA gel shift assay with radiolabeled GAR
RNA and purified gst protein (gst) or purified gst SRp55 protein (gst SRp55). Increasing amounts of unlabeled even at high concentrations of
GAR RNA (competitor). Free and bound probe are indicated. C, RNA gel shift assay with radiolabeled HPV-1 RNA SRp40 and causes production of
named AUM/UM (34) and purified gst protein (gst) or purified gst SRp55 protein (gst SRp55). The AUM/UM RNA
is 57 nucleotides and has an AU content of 76%, and the sequence of the AUM/UM mRNA is the following: 13a7 vpr mRNA, demonstrating
that SRp40 and SRp55 are competAUACCUAUUAGUAGAUUACCUAUUAUAUAUUCCUAUAUUCCUAUACUUCCUAUACUU.
ing for the HIV-1 pre-mRNA. Similarly, SRp55 overrides the potent
GAR enhancer that likely functions
so well in many cell types as a result
of high levels of endogenous ASF/
SF2. Although the predicted SRp55
binding site in GAR overlaps with
the SRp40 binding site, and binding
of SRp55 to this site may inhibit
binding of SRp40, it is questionable
if steric hindrance explains the
inhibitory effect of SRp55. Although
SRp55 binds to GAR and acts at
least partly through GAR, its mechanism of splicing inhibition is likely
to be more complex than mere
physical hindrance of binding of
other splicing factors to nearby
sites. This is also reflected by the
requirement for the SRp55 RS
FIGURE 9. A, Northern blot with RNA extracted from HeLa cells transfected with plasmid pNL13a7 (7) (Fig. 1A) in
the absence or presence of CMV promoter-driven plasmid expressing SRp40 and serially diluted CMV pro- domain for inhibition of splicing.
moter-driven plasmids expressing SRp55 or SRp75. The blot was probed with exon 1 probe (Fig. 1A) detect- These results suggest that SRp55
ing all mRNAs. Identified mRNAs are indicated. B, acrylamide gel showing RT-PCR with oligonucleotides interacts with an unknown factor to
Exon3s and BAMA (Fig. 1A) on cytoplasmic RNA from HeLa cells transfected with pDP (Fig. 2A) in the
absence or presence of CMV promoter-driven plasmid expressing SRp55 or SRp55-dRS, which is lacking inhibit splicing from the 5⬘-splice
the RS domain. vpr, tat, and nef mRNAs are indicated. M represents the molecular weight marker. site of exon 3. This factor could be
C, agarose gels showing RT-PCR reactions with oligonucleotides Exon3s and BAMA (Fig. 1A) on cytoplas- another SR protein.
mic RNA from HeLa cells transfected with pNL13A7 in the absence or presence of 133 nM siRNA against
Overexpression of SR proteins
SRp55 and SRp75 (SMARTpool Dharmacon). The lower panel shows RT-PCR on cytoplasmic RNA from HeLa
cells transfected with pNL13A7 in the absence or presence of either 133 nM or 27 nM of siRNAs against with the infectious molecular clone
SRp55 and SRp75 (SMARTpool Dharmacon). The right panel shows RT-PCR on SRp55 mRNA in the absence
pNL43 revealed that high levels of
or presence of siRNAs against SRp55 and -75.
ASF/SF2 induced production of vpr
HPV-16. Previously published results demonstrated that GAR mRNA, at the same time causing a dramatic decrease in gag,
was primarily dependent on ASF/SF2 and ASF/SF2-sites pol, and env proteins as well as virus production (40). These
located in GAR and at SA5 (25), whereas the SRp40 site in GAR authors speculate that ASF/SF2 enhances splicing to the
contributed less to GAR function. Other investigators have 3⬘-splice site of exon 3, either through a yet unidentified splicdemonstrated that SRp40 enhances splicing to exon 4 (39). Our ing enhancer, or by inhibiting a previously identified splicing
results confirm that overexpression of SRp40 enhances splicing to silencer in exon 3 named ESSV (10, 17). This splicing silencer
SA4, at the expense of SA4a, SA4b, SA4c, and SA5. These results interacts with heterogeneous nuclear ribonucleoprotein A/B
suggest that SRp40 may act on multiple sites in exon 4, upstream (10, 17, 41), and ASF/SF2 is known to counteract heterogeneof SA5. Deletions that we introduced in exon 4 lowered the effect ous nuclear ribonucleoprotein A1, another member of the hetof SRp40 (Fig. 5). So did the deletion of GAR (Fig. 6). One may erogeneous nuclear ribonucleoprotein family (42, 43). Howspeculate that SRp40 interacts with multiple sites in exon 4, ever, ASF/SF2 binds to the GAR enhancer and is necessary for
gaagaagcggagacagcgacgaagagcucauca
SRp55 SRp40
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splicing to exons 4a and 5 (25, 26). In contrast, overexpression
of ASF/SF2 promotes production of the partially spliced vpr
and overrides the function of GAR, much like SRp55 (39, 40).
Because both ASF/SF2 and SRp55 can bind to exon 5, one may
speculate that these interactions in combination with other
binding sites only occupied in the presence of high levels of
ASF/SF2 or SRp55, may inhibit splicing from exon 3 to exons 4,
4a, 4b, 4c, and 5 thereby creating the vpr mRNA. ASF/SF2 and
SRp55 may induce production of vpr mRNA in a similar manner. In HIV-1-infected cells, levels of various SR proteins may
change during the infection (44), or HIV-1 has adapted to the
intracellular levels of SR proteins in T cells and monocyte/
macrophages to optimize production of sufficient quantities of
each alternatively spliced HIV-1 mRNA. Nevertheless, it is
clear that HIV-1 alternative splicing and virus production are
sensitive to minor changes in intracellular concentrations of
various SR proteins (40, 45).
Recently it was shown that splicing to exon 2A, another
incompletely spliced HIV-1 exon that encodes the vif gene,
appears to be positively regulated by SRp75 through the interaction of SRp75 with an enhancer in this region (46, 47). We
show that SRp75 can induce production of vpr mRNA by inhibiting the 5⬘-splice site of exon 3. Our experiments revealed that
deletions in exon 3 enhanced splicing from the 5⬘-splice site of
exon 3 (Fig. 4). This is in line with previously published results
that identified a splicing silencer named ESSV in exon 3 (10, 12).
However, our results do not support an interaction between
SRp75 and sequences in exon 3. It appears that splicing of the
two partially spliced HIV-1 mRNAs 12a7 (vif) and 13a7 (vpr) is
differently regulated.
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